Abstract | OBJECTIVE: STUDY DESIGN: One hundred thirty-nine biopsy-proven OLP patients were randomly assigned to cyclosporine (68) or steroid (71) applied onto the target lesion and affected areas. Assessments were at weeks 0, 2, 4, 8 by clinical scoring and grid measurement of the target lesion (reticulation, erythema, ulceration). Patients ranked severity of pain and burning sensation using visual analog scales. RESULTS: Although clinical response, pain, burning sensation, area of reticulation, erythema, and ulceration at week 4 were all worse in patients receiving cyclosporine than in those receiving steroid, the differences were not statistically significant. Large patient-to-patient variability was evident over the observation period, with little evidence of marked changes in levels over time in both treatment groups. CONCLUSION:
|
Authors | Poon Choy Yoke, Goh Bee Tin, Myung-Jin Kim, Annabelle Rajaseharan, Shaheen Ahmed, Kobkan Thongprasom, Mantharop Chaimusik, Shirley Suresh, David Machin, Wong Hwee Bee, Jorgen Seldrup, Asian Lichen Planus Study Group |
Journal | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
(Oral Surg Oral Med Oral Pathol Oral Radiol Endod)
Vol. 102
Issue 1
Pg. 47-55
(Jul 2006)
ISSN: 1528-395X [Electronic] United States |
PMID | 16831672
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Orabase
- Cyclosporine
- Triamcinolone Acetonide
- Carboxymethylcellulose Sodium
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Aged
- Carboxymethylcellulose Sodium
(analogs & derivatives)
- Child
- Cyclosporine
(therapeutic use)
- Female
- Glucocorticoids
(administration & dosage, therapeutic use)
- Humans
- Immunosuppressive Agents
(administration & dosage, therapeutic use)
- Lichen Planus, Oral
(drug therapy)
- Male
- Middle Aged
- Odds Ratio
- Pain Measurement
- Patient Satisfaction
- Regression Analysis
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage, therapeutic use)
|